With a solid foundation in molecular biology and bioinformatics, I am keen to integrate laboratory skills with advanced data analysis techniques. My primary interests lie in genomics and proteomics, and I have expertise in molecular docking, molecular dynamics simulation, toxicology analysis, and ADMET analysis. My career goal is to bridge the gap between experimental research and data analysis, contributing to the advancement of scientific research.

I am a Junior Researcher at CINTESIS (Universidade do Algarve, Portugal). Research Interests | I use Computational Biology as a way of answering biologically relevant questions. My research interests are focused on understanding how gene expression profiles translate into robust genetic modules that explain the phenotypic plasticity observed in healthy and diseased cells, particularly cancer. I am passionate about Open Science and I am always keen on establishing new collaborations. Current Project | I am starting my independent research line studying cancer causality using Structural Causal Models. Previous Research | I have experience with OMICs datasets, which I have used to study breast cancer, genetic regulation in early vertebrate embryo development, in stem cell differentiation, and in mitochondrial evolution. Teaching | I teach Computational Biology at the Universidade do Algarve, and I organize yearly courses on R programming.  Expertise | Cancer genetics, Molecular oncology, R programming (including package development), OMICS data analysis.

Subham Preetam is the Founder & CEO of N BASE. He is a professional biotechnologist in the field of biorobotics, cancer, immunity, biomedical, and nanometerial research. He is dedicated to the advancement of precision medicine and successful preclinical research to enhance the quality of life for individuals. With extensive cross-disciplinary training and experience in translational research, he is currently focused on various research topics, including microrobotics, soft bio-hybrid robots, and quantum nanoparticles for drug delivery. Furthermore, he is involved in developing a bio-fluidics nanomedicine system that leverages the latest drug delivery technologies to create personalized solutions for brain cancer.